Cargando…

Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development

Crimean–Congo hemorrhagic fever virus (CCHFV), a member of the Nairoviridae family and Bunyavirales order, is transmitted to humans via tick bites or contact with the blood of infected animals. It can cause severe symptoms, including hemorrhagic fever, with a mortality rate between 5 to 30%. CCHFV i...

Descripción completa

Detalles Bibliográficos
Autor principal: Ozdarendeli, Aykut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453274/
https://www.ncbi.nlm.nih.gov/pubmed/37627967
http://dx.doi.org/10.3390/diagnostics13162708
_version_ 1785095893770305536
author Ozdarendeli, Aykut
author_facet Ozdarendeli, Aykut
author_sort Ozdarendeli, Aykut
collection PubMed
description Crimean–Congo hemorrhagic fever virus (CCHFV), a member of the Nairoviridae family and Bunyavirales order, is transmitted to humans via tick bites or contact with the blood of infected animals. It can cause severe symptoms, including hemorrhagic fever, with a mortality rate between 5 to 30%. CCHFV is classified as a high-priority pathogen by the World Health Organization (WHO) due to its high fatality rate and the absence of effective medical countermeasures. CCHFV is endemic in several regions across the world, including Africa, Europe, the Middle East, and Asia, and has the potential for global spread. The emergence of the disease in new areas, as well as the presence of the tick vector in countries without reported cases, emphasizes the need for preventive measures to be taken. In the past, the lack of a suitable animal model susceptible to CCHFV infection has been a major obstacle in the development of vaccines and treatments. However, recent advances in biotechnology and the availability of suitable animal models have significantly expedited the development of vaccines against CCHF. These advancements have not only contributed to an enhanced understanding of the pathogenesis of CCHF but have also facilitated the evaluation of potential vaccine candidates. This review outlines the immune response to CCHFV and animal models utilized for the study of CCHFV and highlights the progress made in CCHFV vaccine studies. Despite remarkable advancements in vaccine development for CCHFV, it remains crucial to prioritize continued research, collaboration, and investment in this field.
format Online
Article
Text
id pubmed-10453274
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104532742023-08-26 Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development Ozdarendeli, Aykut Diagnostics (Basel) Review Crimean–Congo hemorrhagic fever virus (CCHFV), a member of the Nairoviridae family and Bunyavirales order, is transmitted to humans via tick bites or contact with the blood of infected animals. It can cause severe symptoms, including hemorrhagic fever, with a mortality rate between 5 to 30%. CCHFV is classified as a high-priority pathogen by the World Health Organization (WHO) due to its high fatality rate and the absence of effective medical countermeasures. CCHFV is endemic in several regions across the world, including Africa, Europe, the Middle East, and Asia, and has the potential for global spread. The emergence of the disease in new areas, as well as the presence of the tick vector in countries without reported cases, emphasizes the need for preventive measures to be taken. In the past, the lack of a suitable animal model susceptible to CCHFV infection has been a major obstacle in the development of vaccines and treatments. However, recent advances in biotechnology and the availability of suitable animal models have significantly expedited the development of vaccines against CCHF. These advancements have not only contributed to an enhanced understanding of the pathogenesis of CCHF but have also facilitated the evaluation of potential vaccine candidates. This review outlines the immune response to CCHFV and animal models utilized for the study of CCHFV and highlights the progress made in CCHFV vaccine studies. Despite remarkable advancements in vaccine development for CCHFV, it remains crucial to prioritize continued research, collaboration, and investment in this field. MDPI 2023-08-19 /pmc/articles/PMC10453274/ /pubmed/37627967 http://dx.doi.org/10.3390/diagnostics13162708 Text en © 2023 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ozdarendeli, Aykut
Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
title Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
title_full Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
title_fullStr Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
title_full_unstemmed Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
title_short Crimean–Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
title_sort crimean–congo hemorrhagic fever virus: progress in vaccine development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453274/
https://www.ncbi.nlm.nih.gov/pubmed/37627967
http://dx.doi.org/10.3390/diagnostics13162708
work_keys_str_mv AT ozdarendeliaykut crimeancongohemorrhagicfevervirusprogressinvaccinedevelopment